Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatic steatosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Hepatic steatosis. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2005-002966-12 Sponsor Protocol Number: MD-04-01 Start Date*: 2005-03-23
    Sponsor Name:TRASTEC
    Full Title: PHYSIOPATHOLOGY OF NONALCOHOLIC HEPATIC STEATOSIS AND EFFICACY OF SILYMARIN IN THE THERAPY OF NONALCOHOLIC HEPATIC STEATOSIS
    Medical condition: Nonalcoholic hepatic steatosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10019708 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007884-26 Sponsor Protocol Number: 1.2 (21.11.2007) Start Date*: 2008-02-13
    Sponsor Name:HUS, HYKS, Diabetesklinikka
    Full Title: Pioglitatsonin käyttö potilailla, joilla krooninen rasvamaksasairaus ja tuore tyypin 2 diabetes
    Medical condition: K76.9 Rasvamaksa E11 Tyypin 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041970 Steatosis hepatic LLT
    9.1 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003231-46 Sponsor Protocol Number: 0001 Start Date*: 2005-11-04
    Sponsor Name:Dept of Internal Medicine IV, Med Uni Vienna
    Full Title: Changes in hepatic lipid content assessed by MR Spectroscopy in patients with non-alcoholic fatty liver disease (NAFLD) under standard therapy (reduction diet and regular aerobic exercise) with and...
    Medical condition: Nonalcoholic fatty liver disease (NAFLD) is a potentially progressive liver disease, leading to cirrhosis in up to 26% of affected patients and rarely hepatocellular carcinoma. Several studies have...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004449-18 Sponsor Protocol Number: HEP201 Start Date*: 2019-04-10
    Sponsor Name:Promethera Biosciences
    Full Title: Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH).
    Medical condition: NASH is characterized by steatosis, inflammation and cytological ballooning with varying amounts of fibrosis. Patients with NASH are at risk of cardiovascular morbidity and mortality. In chronic li...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    20.0 10019805 - Hepatobiliary disorders 10019708 Hepatic steatosis PT
    20.0 10019805 - Hepatobiliary disorders 10041970 Steatosis hepatic LLT
    20.0 10019805 - Hepatobiliary disorders 10019669 Hepatic fibrosis and cirrhosis HLT
    20.0 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    20.0 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    20.1 10019805 - Hepatobiliary disorders 10064704 Decompensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003197-13 Sponsor Protocol Number: ISIS484137-CS2 Start Date*: 2017-11-24
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (ISIS-DGAT2RX, an Antisense Inhibitor of Diacylglycerol Acyltr...
    Medical condition: Hepatic Steatosis in type 2 diabetes (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 10019805 - Hepatobiliary disorders 10019708 Hepatic steatosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000499-83 Sponsor Protocol Number: 1386.4 Start Date*: 2017-05-04
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orall...
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) IE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-006165-18 Sponsor Protocol Number: FEN Start Date*: 2012-06-20
    Sponsor Name:Academic Medical Center
    Full Title: A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects
    Medical condition: Obesity Metabolic syndrome X Insulin resistance Fatty liver
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004515-56 Sponsor Protocol Number: hepatology_MT_2007-08 Start Date*: 2008-04-28
    Sponsor Name:Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG
    Full Title: Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005531-28 Sponsor Protocol Number: Urso in Obese Start Date*: 2008-04-03
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery
    Medical condition: Patients with morbid obesity (MB) are investigated. MB is very frequently (90%) associated with non-alcoholic fatty liver disease (NAFLD) comprising a spectrum reaching from steatosis (NAFL) over s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004986-38 Sponsor Protocol Number: 337HNAS20011 Start Date*: 2022-01-04
    Sponsor Name:Inventiva S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatiti...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Completed) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000203-82 Sponsor Protocol Number: SHP626-201 Start Date*: 2016-11-09
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter...
    Medical condition: Nonalcoholic steatohepatitis (NASH), is a clinical condition occurring in individuals who do not drink excessive alcohol (>20 grams/day), yet have hepatic histology which is indistinguishable from ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-002279-13 Sponsor Protocol Number: MGL-3196-19 Start Date*: 2023-02-28
    Sponsor Name:Madrigal Pharmaceuticals, Inc.
    Full Title: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepati...
    Medical condition: Non-alcoholic Steatohepatitis (NASH) Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009214 Cirrhosis of liver without mention of alcohol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012916-41 Sponsor Protocol Number: CICL670EDE08T Start Date*: 2010-01-12
    Sponsor Name:CROLLL GmbH
    Full Title: The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a prospective open-label phase I/II trial
    Medical condition: To assess the clinical and biological activity of Deferasirox in patients with NASH and increased iron storage / disturbed distribution of iron on liver function and liver histology
    Disease: Version SOC Term Classification Code Term Level
    14.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003010-17 Sponsor Protocol Number: - Start Date*: 2011-07-07
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Randomized double-blind intervention trial to assess the efficacy of vitamin D3 supplementation vs placebo in reducing hepatic steato-inflammation and cardio-metabolic risk profile in patients affe...
    Medical condition: Patients affected by type 2 diabetes and non alcoholic fatty liver disease- non alcoholic steato-hepatitis (NAFLD/NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000295-42 Sponsor Protocol Number: GFT505-212-7 Start Date*: 2012-09-11
    Sponsor Name:GENFIT
    Full Title: A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).
    Medical condition: Patients with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003575-21 Sponsor Protocol Number: Start Date*: 2017-07-25
    Sponsor Name:MRC Clinical Trials Unit at UCL
    Full Title: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy.
    Medical condition: Hepatic steatosis in adults with chronic HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-006069-39 Sponsor Protocol Number: LPS16141 Start Date*: 2022-06-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Parallel-Group Clinical Trial to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care Versus Placebo Added to Standard of Care, in Non-Alcoho...
    Medical condition: Non-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004871 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002984-24 Sponsor Protocol Number: PHS-Px-104-II-01 Start Date*: 2013-10-07
    Sponsor Name:Phenex Pharmaceuticals AG
    Full Title: A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10019805 - Hepatobiliary disorders 10024670 Liver disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004999-19 Sponsor Protocol Number: 191001 Start Date*: 2020-06-16
    Sponsor Name:Department of infectious diseases, Hvidovre Hospital
    Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress...
    Medical condition: Human immunodeficiency viruses (HIV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10067326 Antiretroviral therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001046-19 Sponsor Protocol Number: ORA-D-N01B Start Date*: 2020-08-13
    Sponsor Name:Oramed Ltd.
    Full Title: An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 22:22:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA